ZAI LAB advances global pipeline with three Zoci trials by 2026 end Jan 13, 2026 08:02AM
Zai Lab Highlights Strategic Priorities and Global Pipeline Progress at 44th Annual J.P. Morgan Healthcare Conference Jan 13, 2026 08:00AM
China approves Zai Lab's AUGTYRO for NTRK-positive solid tumors Jan 6, 2026 07:30AM
Zai Lab Announces National Medical Products Administration (NMPA) Approval of AUGTYRO™ (repotrectinib) for Patients with NTRK-Positive Solid Tumors Jan 6, 2026 07:30AM
Zai Lab to Present at 44th Annual J.P. Morgan Healthcare Conference Jan 5, 2026 07:30AM
View Older Stories

Dec 23, 2025 07:31AM Zai Lab Limited (ZLAB) Zai Lab receives China approval for schizophrenia drug COBENFY
Dec 23, 2025 07:30AM Zai Lab Announces Approval of COBENFY (xanomeline and trospium chloride) in China, a First-in-Class Therapy for Schizophrenia
Jun 30, 2025 09:06AM Zai Lab Limited (ZLAB) Announces Positive Topline Phase 3 Results for Bemarituzumab
Jun 30, 2025 09:05AM Zai Lab Announces Positive Topline Phase 3 Results for Bemarituzumab in Fibroblast Growth Factor Receptor 2b (FGFR2b) Positive First-Line Gastric Cancer
Jun 13, 2025 07:00AM Zai Lab Presents New Preclinical Data for ZL-1503, an IL-13/IL-31R Bispecific Antibody for the Treatment of Atopic Dermatitis, at EAACI Congress 2025
Jun 2, 2025 07:01AM Zai Lab Limited (ZLAB) Presents Positive Phase 1 Data for ZL-1310
Jun 2, 2025 07:00AM Zai Lab Presents Positive Phase 1 Data for ZL-1310, a DLL3-Targeted ADC, Demonstrating Robust Anti-Tumor Activity and Safety in Patients with Extensive-Stage Small Cell Lung Cancer at 2025 ASCO Annual
May 31, 2025 03:08PM Zai Lab and Novocure Announce Results From the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting
May 19, 2025 07:02AM Zai Lab (ZLAB) Receives U.S. FDA Fast Track Designation for ZL-1310
May 19, 2025 07:00AM Zai Lab Receives U.S. FDA Fast Track Designation for ZL-1310, a DLL3-Targeted Antibody-Drug Conjugate, for Treatment of Extensive-Stage Small Cell Lung Cancer
Apr 23, 2025 10:56AM Zai Lab to Present Data from Phase 1 Trial of DLL3-Targeted Antibody-Drug Conjugate (ADC) ZL-1310 at 2025 ASCO Annual Meeting
Jan 22, 2025 11:16PM Zai Lab Limited (ZLAB) Receives Orphan Drug Designation from the U.S. FDA for ZL-1310
Jan 22, 2025 11:15PM Zai Lab Receives Orphan Drug Designation from the U.S. FDA for ZL-1310 (DLL3 ADC) for the Treatment of Small Cell Lung Cancer (SCLC)
Jan 17, 2025 07:30AM Zai Lab (ZLAB) Announces Acceptance of New Drug Application for KarXT for the Treatment of Schizophrenia
Jan 17, 2025 07:30AM Zai Lab Announces Acceptance of New Drug Application for KarXT for the Treatment of Schizophrenia
Jan 15, 2025 07:30AM Zai Lab Limited (ZLAB) Announces Positive Topline Results for TIVDAK in the China Subpopulation of the Global Phase 3 innovaTV 301 Trial
Jan 15, 2025 07:30AM Zai Lab Announces Positive Topline Results for TIVDAK in the China Subpopulation of the Global Phase 3 innovaTV 301 Trial in Patients with Recurrent or Metastatic Cervical Cancer
Jan 9, 2025 06:30PM Zai Lab Announces Strategic Partnership with MediLink Therapeutics to Develop a Novel LRRC15 Antibody-Drug Conjugate
Dec 12, 2024 07:30AM Zai Lab Announces Participation in Investor Conference in January 2025
Dec 2, 2024 07:03AM Zai Lab Limited (ZLAB) and Novocure (NVCR) Report Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields
Dec 2, 2024 07:02AM Zai Lab and Novocure Announce Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer
Nov 27, 2024 11:05PM Zai Lab Announces the Inclusion of AUGTYRO® (repotrectinib) for ROS1+ NSCLC and Other Updates in China’s National Reimbursement Drug List
Nov 21, 2024 04:00AM Zai Lab and Pfizer Announce Strategic Collaboration on the Novel Antibacterial Drug XACDURO® (Sulbactam-Durlobactam)
Nov 12, 2024 06:30AM Zai Lab Announces Third Quarter 2024 Financial Results and Recent Corporate Updates
Nov 11, 2024 07:31AM Zai Lab Limited (ZLAB) and argenx (ARGX) Announce Approval of VYVGART Hytrulo
Nov 11, 2024 07:30AM Zai Lab and argenx Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China
Oct 29, 2024 07:31AM Zai Lab (ZLAB) Reports Positive Topline Data from Phase 3 Bridging Trial Evaluating KarXT for the Treatment of Schizophrenia in China
Oct 29, 2024 07:30AM Zai Lab Reports Positive Topline Data from Phase 3 Bridging Trial Evaluating KarXT for the Treatment of Schizophrenia in China
Oct 24, 2024 05:15AM ZL-1310, an Investigational DLL3-Targeted Antibody-Drug Conjugate (ADC), Demonstrates Promising Objective Response Rates and Safety Profile in Extensive-Stage Small Cell Lung Cancer
Oct 18, 2024 07:30AM Zai Lab Announces Participation in November and December Investor Conferences
Oct 17, 2024 08:00AM Zai Lab to Host Webcast Presentation to Discuss Data from Early Clinical Program Evaluating Its Investigational DLL3-Targeted Antibody-Drug Conjugate (ADC) ZL-1310
Oct 16, 2024 07:30AM Zai Lab to Announce Third Quarter 2024 Financial Results and Recent Corporate Updates on November 12, 2024
Oct 9, 2024 07:00AM Zai Lab to Present Data from Phase 1 Trial of ZL-1310, Its Investigational Antibody-Drug Conjugate (ADC) for DLL3+ Solid Tumors, at EORTC-NCI-AACR Symposium (ENA) 2024
Sep 17, 2024 01:32PM Zai Lab to Present Preclinical Data of ZL-1503, an IL-13/IL-31 Bispecific Antibody for the Treatment of Atopic Dermatitis, at EADV Congress 2024
Aug 27, 2024 08:32AM Zai Lab (ZLAB) to Present Preliminary Data From Phase 1 Trial of ZL-1218
Aug 27, 2024 08:30AM Zai Lab to Present Preliminary Data From Phase 1 Trial of ZL-1218, an Investigational Anti-CCR8 Antibody for the Treatment of Advanced Solid Tumors, at ESMO Congress 2024
Aug 22, 2024 07:30AM Zai Lab Announces Participation in September Investor Conferences
Aug 6, 2024 04:05PM Zai Lab Announces Second Quarter 2024 Financial Results and Recent Corporate Updates
Jul 16, 2024 12:15AM Zai Lab and argenx Announce Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in China
Jul 15, 2024 02:53PM Zai Lab (ZLAB) -Supported Study Published in Cell Provides New Insights with Potential to Improve Treatment of HRD-Positive Ovarian Cancers
Jul 15, 2024 02:53PM Zai Lab-Supported Study Published in Cell Provides New Insights with Potential to Improve Treatment of HRD-Positive Ovarian Cancers, Including Through Combination PARP Inhibitor and CCR8 Therapy
Jul 10, 2024 07:30AM Zai Lab to Announce Second Quarter 2024 Financial Results and Recent Corporate Updates on August 6, 2024
Jun 11, 2024 04:05PM Zai Lab Announces Dr. Harald Reinhart to Retire as Head of Global Development for Neuroscience, Autoimmune and Infectious Diseases; Dr. Rafael Amado to be Appointed President, Head of Global R&D
May 22, 2024 07:30AM Zai Lab Initiates Global Phase 2 Clinical Trial Evaluating ZL-1102 As a Topical Treatment for Chronic Plaque Psoriasis
May 20, 2024 05:54AM Zai Lab Limited (ZLAB) and Innoviva Specialty Therapeutics Announce NMPA Approval for XACDURO
May 20, 2024 12:21AM Zai Lab and Innoviva Specialty Therapeutics Announce NMPA Approval for XACDURO® (Sulbactam-Durlobactam or SUL-DUR) for Hospital-Acquired and Ventilator-Associated Pneumonia Caused by Acinetobacter Ba
May 16, 2024 07:30AM Zai Lab Announces Participation in May and June Investor Conferences
May 14, 2024 07:31AM Zai Lab Limited (ZLAB) Announces Acceptance of sBLA with Priority Review for Efgartigimod Alfa Injection in China
May 14, 2024 07:30AM Zai Lab Announces Acceptance of Supplemental Biologics License Application with Priority Review for Efgartigimod Alfa Injection (Subcutaneous Injection) in Chronic Inflammatory Demyelinating Polyneuro
May 13, 2024 05:47AM Zai Lab Limited (ZLAB) Announces Approval of AUGTYRO in China
View Older Stories